Gene
MYD88
MYD88 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (21), Actionable biomarkers (1), Trial mentions (25), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention MYD88. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 18 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 8 of 8,875 | 0.09% | not measured | |
| 2024 | 2 of 8,597 | 0.02% | not measured | |
| 2023 | 3 of 8,275 | 0.04% | 39 of 11,460 | 0.34% |
| 2022 | 2 of 8,285 | 0.02% | 48 of 13,598 | 0.35% |
| 2021 | 3 of 8,692 | 0.03% | 63 of 15,045 | 0.42% |
| 2020 | 1 of 7,640 | 0.01% | 74 of 14,459 | 0.51% |
| 2019 | 2 of 7,300 | 0.03% | 51 of 12,159 | 0.42% |
| 2018 | 0 of 6,927 | 0.00% | 46 of 11,854 | 0.39% |
| 2017 | 1 of 6,558 | 0.02% | 59 of 11,595 | 0.51% |
Showing 10 of 37 years.
Assay-provider ledger (21)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| HOLOGIC | Diagnostic provider | Analytical validation | 1 | November 03, 2025 |
| Leica BioSystems | Unclassified | Analytical validation | 1 | November 03, 2025 |
| Menarini Biomarkers Singapore Pte Ltd | Diagnostic provider | Analytical validation | 1 | November 03, 2025 |
| ROCHE Pte Ltd | Context dependent | Analytical validation | 1 | November 03, 2025 |
| Agilent Technologies | Reagent supplier | Clinical validationAnalytical validation | 3 | March 01, 2025 |
Showing 5 of 21 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| MYD88 (L265P) | IBRUTINIB | response-associated | macroglobulinemia | Cancer Genome Interpreter |
Trial mentions (25)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT05911802 | Trial biospecimen (AACT) |
| NCT04263480 | Trial eligibility (AACT) |
| NCT06779435 | Trial eligibility (AACT) |
| NCT07108998 | Trial eligibility (AACT) |
| NCT04273139 | Trial eligibility (AACT) |
Showing 5 of 25 trial mentions.
Target-disease associations (635)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Abnormality of the pancreas | phenotype | Literature (Europe PMC) |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
| Ampulla of Vater Carcinoma | cancer or benign tumor | Cancer Gene Census |
| Angel-shaped phalango-epiphyseal dysplasia | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Anorexia | phenotype | Literature (Europe PMC) |
Showing 5 of 635 associations.
Vendor sourcing (95)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is observed at an extremely low frequency in the gnomAD v4.1.0 dataset (total allele frequency: <0.001%). Predicted Consequence/Location: Stop-ga... | View ClinVar record SCV007610501.1 |
| AbbVie Inc. | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Participants must meet the following criteria on screening examination to be eligible to participate. Screening evaluations including consent, physical ... | View trial NCT04273139 |
| AbbVie Inc. | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Proven clinicopathological diagnosis of WM as defined by consensus panel one of the Second International Workshop on WM (IWWM). Histopathology has to be... | View trial NCT05099471 |
| AbbVie Inc. | Trial collaborator | Mentioned in trial textTrial free-text mention | MYD88 | View trial NCT05099471 |
| AbbVie Inc. | Trial collaborator | Mentioned in trial textTrial free-text mention | MYD88 | View trial NCT04273139 |
Showing 5 of 95 sourcing records.
Trial-cited literature (700)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Multi-modal data to identify key factors influencing lung injury in ARDS patients undergoing invasive mechanical ventilation: A prospective multi-center observational study protocol. | PloS one | 2026 | 1 |
| Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia. | Blood advances | 2025 | 8 |
| From Fork to Brain: The Role of AGE-RAGE Signaling and the Western Diet in Neurodegenerative Disease. | NeuroSci | 2025 | 4 |
| Immune Signatures Distinguish Pure and Mixed Sepsis in Critical COVID-19: A Retrospective Cohort Study. | Journal of inflammation research | 2025 | 3 |
| Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenström macroglobulinemia: a pooled analysis. | Blood advances | 2025 | 1 |
Showing 5 of 700 papers.
Protein variant mentions (4)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A35R | 1 | 2022 | PMID 36263798 |
| p.L252P | 59 | 2011 to 2025 | PMID 40279539, PMID 37496419, PMID 38984103 |
| p.L256P | 1 | 2021 | PMID 33207010 |
| p.Q2140X | 1 | 2021 | PMID 33856277 |
Literature-extracted relations (71)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Lipopolysaccharides | Chemical | associate |
Downregulation of Inflammatory Cytokine Release from IL-1β and LPS-Stimulated PBMC Orchestrated by ST2825, a MyD88 Dimerisation Inhibitor. | 2020 |
| Peptides | Chemical | negative_correlate |
Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment. | 2020 |
| DOCETAXEL | Chemical | associate |
Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance. | 2017 |
| Lipopolysaccharides | Chemical | associate |
Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance. | 2017 |
| (LMW)heparin | Chemical | negative_correlate |
Role of heparin in pulmonary cell populations in an in-vitro model of acute lung injury. | 2017 |
Showing 5 of 71 relation assertions.
Organizations publishing (568)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 29 | 2009 to 2024 |
| Dana-Farber Cancer Institute | Other | 26 | 2011 to 2025 |
| Harvard Medical School | Academic | 23 | 2009 to 2025 |
| Mayo Clinic | Hospital | 18 | 2009 to 2023 |
| Stanford University | Academic | 13 | 2010 to 2023 |
Showing 5 of 568 organizations.
Where MYD88 appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
589 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.